- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 275892, 9 pages
Hunting for Serine 276-Phosphorylated p65
Laboratory of Eukaryotic Gene Expression (LEGEST), Department of Physiology, Ghent University, K.L. Ledeganckstraat 35, 9000 Ghent, Belgium
Received 13 August 2009; Revised 11 November 2009; Accepted 17 November 2009
Academic Editor: Susan A. Rotenberg
Copyright © 2010 Anneleen Spooren et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The transcription factor nuclear factor kappaB (NF-B) is one of the central mediators of inflammatory gene expression. Several posttranslational modifications of NF-B, regulating its transactivation ability, have been described. Especially phosphorylation of the NF-B subunit p65 has been investigated in depth and several commercial phosphospecific antibodies, targeting selected p65 residues, are available. One of the p65 residues, that is subject to phosphorylation by protein kinase A (PKA) as well as by mitogen-stimulated kinase-1 (MSK-1), is the serine at position 276. Here, we have performed a detailed analysis of the performance of the most commonly used commercial anti-P-p65 Ser276 antibodies. Our findings indicate that at least three widely used anti-P-p65 Ser276 antibodies do not detect p65 in vivo via Western Blot, but instead crossreact with PKA-regulated proteins. As PKA is one of the main kinases responsible for phosphorylation of p65 at Ser276, this observation warrants cautious interpretation of data generated using the tested antibodies.
The transcription factor nuclear factor kappaB (NF-κB) was originally identified as the factor driving immunoglobulin transcription in B-cells . Since then evidence has accumulated, identifying NF-κB as the master regulator of inflammatory gene expression in a variety of cell types [2, 3]. The NF-κB family of transcription factors consists of a group of proteins (p50/p105, p52/p100, p65 (relA), c-Rel, and RelB), all of which contain the N-terminal Rel-homology domain (RHD), that is responsible for their DNA-binding and homo- or heterodimerization ability. In addition, p65, c-Rel and RelB also contain a transactivation domain (TAD). The NF-κB proteins are kept in the cytoplasm through physical interaction with inhibitors of the IκB (inhibitor of κB) family. In response to proinflammatory cytokines or pathogen-associated molecular patterns, the IκB kinase (IKK), an upstream kinase complex, is activated. Activated IKK phosphorylates the IκB molecules, targeting them for ubiquitination-dependent degradation, and allowing the migration of NF-κB dimers to the nucleus, where they can activate gene transcription. More recent studies have shown that, in many instances, IκB degradation and consequent NF-κB nuclear translocation are not sufficient for full-blown NF-κB-dependent gene expression. A multitude of posttranslational modifications of the NF-κB subunits, affecting their transactivation ability, has indeed been described [4–7].
The prototypical, most studied, NF-κB complex is the p50-p65 dimer, and especially posttranslational modifications of the p65 subunit have been investigated in great detail. The p65 residue contains several serine residues, which have been shown to be subject to phosphorylation [5, 8]. One of the p65 serine residues, which was originally shown to be phosphorylated by the protein kinase A (PKA) upon lipopolysaccharide (LPS) triggering, is the serine at position 276 . Later it was discovered that the p65 serine 276 (Ser276) residue is also a target of the mitogen- and stress-activated kinase-1 (MSK-1) after TNF-α stimulation . Since its original demonstration in 1997, the role of phosphorylation of the p65 Ser276 residue has been intensively studied, and the phosphorylation has been shown to be involved in the expression of a variety of NF-κB-dependent genes, in different cell types and upon different stimuli. Most studies agree that Ser276 phosphorylation is required for the recruitment of the transcriptional coactivator CBP (CREB-binding protein) and, hence, activates transcription of particular p65 target genes [10, 11]. Very recently, a “knock-in” mouse, expressing p65 with the Ser276 mutated to alanine was generated . Unfortunately these mice showed a variegated phenotype, making it difficult to interpret the physiological function of p65 Ser276 phosphorylation.
Most of the reports investigating the function of p65 Ser276 phosphorylation have made use of a commercial antibody (Cell Signaling no. 3037), directed against the phosphorylated p65 Ser276 residue (for a complete list of publications in which anti-phospho-p65 Ser276 antibodies were used, we refer toSupplementary Table in Supplementary Material available online at doi:10.1155/2009/275892).This antibody was generated using a synthetic Keyhole limpet hemocyanin (KLH)-coupled phosphopeptide, corresponding to the amino acid residues surrounding Ser276 of human NF-κB p65.
In this study, we have summarized our experimental data obtained with the Cell Signaling no. 3037 and three other commonly used anti-phospho(P)-p65 Ser276 antibodies. Our findings suggest these antibodies are not suitable for detection of Ser276-phosphorylated p65 in vivo by Western Blotting and indicate that studies into the function of p65 Ser276 phosphorylation should be supported by additional, antibody-independent assays.
2. Materials and Methods
Isoproterenol (iso), forskolin, phorbol 12-myristate 13-acetate (PMA), chloro-phenyl-thio-cAMP (cAMP), H89, and lipopolysaccharide (LPS) were purchased from Sigma-Aldrich (St. Louis, MO). Recombinant human tumor necrosis factor- (TNF-) was obtained from the Department of Molecular Biology of Gent University (DMBR, Gent, Belgium). siPKAc (M-004649-01), sip65 (M-003533-02), sip105/p50 (M-003520-01), and si-c-Rel (M-004768-01) SMART pools and siControl (D-001210-05) were from Dharmacon (Lafayette, CO).
2.2. Primary Antibodies
Four rabbit polyclonal antibodies directed against the phosphorylated Ser276 residue of p65 were used in this study: anti-P-p65 Ser276 (no. 3037) from Cell Signaling (Danvers, MA), anti-P-p65 Ser276 (no. 11011) from Signalway Antibody (SAB, Pearland, TX), anti-P-p65 Ser276 (no. 100-401-264) from Rockland (Gilbertsville, PA), and a homemade anti-P-p65 Ser276 antibody (kind gift of Prof. Dr. P. Cohen, University of Dundee, UK; produced and purified by Drs. C. Armstrong and J. Leitch). Anti-p65 (C-20), anti-CBP, anti-p105/p50, anti-c-Rel, and anti-PKAc were from Santa Cruz (Santa Cruz, CA). Anti-tubulin was from Sigma-Aldrich (St. Louis, MO).
2.3. Cell Culture
L929sA mouse fibroblasts were described previously . Raw264.7 mouse macrophages, C2C12 mouse myoblasts, and L363 human multiple myeloma cells were obtained from the European Collection of Cell Cultures (Salisbury, UK). The human astrocytoma cell line 1321N1 was a kind gift from Prof. Dr. Müller (University of Bonn, Germany). NF-κB p65-deficient, and wild type p65 (wt p65) or p65 Serine to alanine mutated (p65 S/A) reconstituted, mouse embryonic fibroblasts (MEFs) were a gift from Dr. Okazaki (Juntendo University, Japan). L363, Raw264.7, and C2C12 cells were maintained in RPMI-1640 with Glutamax-I, supplemented with 10% FCS, 100 U/mL penicillin, and 100 g/mL streptomycin. All other cells were cultured in DMEM with 10% FCS, 100 U/mL penicillin and 100 g/mL streptomycin. Cells were maintained at 37°C in a humidified 5% atmosphere. Adherent cells were passaged using 0,05% (w/v) of trypsin in 0,4% (w/v) EDTA (all cell culture reagents were from Invitrogen, Carlsbad, CA).
2.4. Western Blotting
Total cellular extracts were made in SDS sample buffer (62,5 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 0,5% -mercapto-ethanol). Equal amounts of total lysates from each condition were resolved by 8,5% SDS-PAGE, transferred onto nitrocellulose membranes and analysed by Western Blotting. Chemiluminescent detection was performed using horse-radish peroxidase (HRP)-coupled secondary antibodies and Western lightning chemiluminescent reagent plus (Perkin Elmer LifeSciences, Boston, MA) on the Kodak image station 440CF. For applications that required higher sensitivity, Immobilion Nitrocellulose was used, in combination with fluorescent secondary antibodies (Rockland, Gilbertsville, PA). Detection was performed on the Odyssey Imaging System (Licor, Lincoln, NA). For preadsorption of the antibodies in blocking experiments, twice the volume of P-p65 Ser276 blocking peptide (Cell Signaling, no. 1437) as volume of P-p65 Ser276 antibody was combined and incubated for 30 minutes at 4°C, prior to adding the antibody/peptide mixture to the blots.
2.5. siRNA Silencing of p65 and PKAc
For siRNA experiments cells were seeded in 6 wells (200000 cells/well) and transfected using the calcium phosphate method with 50 nM siGENOME SMART pools. siControl-transfected samples were used to assess aspecific effects. 48 hours after transfection and after overnight starvation, cells were induced for the indicated time periods. Subsequently, cells were lysed in SDS sample buffer for Western Blotting analysis.
2.6. In Vitro Kinase Assay
Recombinant GST-p6512-317 and the S276C-mutated version were produced and purified according to the manufacturer's instructions (Amersham Pharmacia Biotech, Rainham, UK). 2 M of the protein was incubated at 30°C for 20 min in kinase buffer (50 mM Tris pH 7.4, 10 mM Mg(Ac)2, 0.1 mM EGTA, and 0.1% -mercaptoethanol), supplemented with 0.1 mM ATP and 15 ng of recombinant active MSK-1 (Upstate, Billerica, MA). 250 ng of recombinant proteins were subsequently spotted on nitrocellulose membrane, or separated via SDS-PAGE, and subjected to Western Blotting.
3.1. Anti-Phospho-p65 Ser276 (Cell Signaling no. 3037) Detects a Prominent 130 kDa Band, and a Weak 80 kDa Band, Induced by Different Stimuli (LPS, PMA, TNF, cAMP, Forskolin, Isoproterenol) in Different Cell Types. Both Bands Can Be Blocked with the Phosphopeptide Used for Immunization
The anti-phospho-p65 Ser276 (no. 3037), distributed by Cell Signaling (Danvers, MA), was generated in rabbits using a synthetic, KLH-coupled phosphopeptide, corresponding to the residues surrounding Ser276 of human p65. According to the accompanying data sheet, the antibody only detects p65 when it is phosphorylated at the Ser276 residue. Additional information supplied by the datasheet is that, whereas it was generated using a human peptide, the antibody crossreacts with mouse and rat (and possibly dog) P-Ser276 p65. Also according to the data sheet, Ser276-phosphorylated p65 migrates at 80 kDa, instead of the expected 65 kDa, in reducing gels. As shown in Figure 1, we detected several immunoreactive bands in lysates from different human (L363, 1321N1, A549) and mouse (L929sA, Raw264.7, C2C12) cell types. Phosphorylation of p65 at Ser276 has been described after cAMP-independent activation of PKA by LPS , as well as after cAMP-dependent stimulation of PKA by the adenylyl cyclase activator forskolin . In addition, p65 was phosphorylated at Ser276 by MSK-1 upon TNF-α treatment . We indeed observed that signals activating PKA (LPS, cAMP, isoproterenol and forskolin) or MSK-1 (TNF, PMA) induced immunoreactive bands recognized by the Cell Signaling no. 3037 antibody. In all investigated cell types, the major immunoreactive band, induced by all investigated stimuli, migrated with an apparent molecular weight (MW) of 130 kDa (arrow 1). In most cell types, a minor 80 kDa band (arrow 2), as expected based upon the information supplied by the Cell Signaling datasheet, was also induced. To investigate whether these immunoreactive bands represent specific interactions with sequences homologous to that of the phosphopeptide used for immunization, we performed blocking experiments in which the anti-P-p65 Ser276 antibody was preadsorbed with this phosphopeptide. As demonstrated in Figure 1, both the 80 and 130 kDa induced immunoreactivities disappeared when the blots were incubated with preadsorbed anti-P-p65 Ser276 antibody, indicating that the immunoreactivity is indeed the result of a specific interaction with an amino acid sequence homologous to that of the immunizing phosphopeptide.
3.2. The Cell Signaling no. 3037-Detected Bands Are Not Abrogated upon siRNA Mediated Knock-Down of p65
Because we observed, unexpectedly, that cAMP-activating signals, such as isoproterenol or forskolin, in addition to the 80 kDa band described in the Cell Signaling no. 3037 datasheet, potently induced a 130 kDa band that was recognized in a specific manner by the Cell Signaling no. 3037 antibody in different cell types, we further investigated the authenticity of this band using an siRNA approach in the 1321N1 human astrocytoma. As shown in Figure 2, whereas our siRNA approach led to efficient knock-down of p65 (A2, B2), the 130 kDa, isoproterenol-induced immunoreactivity detected by Cell Signaling no. 3037, did not disappear or even diminish (A1). Moreover, the 80 kDa, presumable P-Ser276 p65, band, induced by isoproterenol and, to a lesser extent, TNF-, also remained equally apparent in cells were p65 expression was silenced (Figure 2, A1). As a control, we also investigated whether p65 knock-down abrogated TNF-α-induced phosphorylation of p65 at Serine 536. As evident from Figure 2, the anti-P-p65 Ser536 antibody recognizes a 65 kDa immunoreactivity (B1) induced by TNF-α, that comigrates with unphosphorylated p65 (Figure 2, B2) and is indeed inhibited when p65 is silenced. Equal loading of the gels was confirmed by detection of tubulin (A3, B3).
3.3. Other Anti-Phospho-p65 Ser276 Antibodies Display the Same Immunoreactivity as the Cell Signaling no. 3037 Antibody. The Bands Detected by All Presumable P-p65-Ser276-Specific Antibodies Are Not p65, But Unrelated PKA-Regulated Proteins
To investigate whether other available antibodies would perhaps be more useful to detect Ser276 phosphorylated p65 via Western Blotting, we investigated phosphorylation of p65 at Ser276 using two anti-P-p65 Ser276 antibodies distributed by independent companies (no. 11011 from SAB and no. 100-401-264 from Rockland). In addition, we used a homemade antibody (kind gift of Prof. P. Cohen, University of Dundee, UK) that was previously used to demonstrate Ser276 phosphorylation of p65 (10). As apparent from Figure 3, like Cell Signaling no. 3037 (B3), both SAB no. 11011 (A1) and Rockland no. 100-401-264 (B1) and the homemade antibody (C1) detect a major 130 kDa band (upper arrow), in isoproterenol-treated cells. The SAB no. 11011 and homemade antibodies also detect the 80 kDa inducible band (lower arrow), whereas this band was not apparent with the Rockland no. 100-401-264 antibody. The SAB no. 11011 and homemade antibodies in addition recognize several high molecular weight bands, some of which are induced by isoproterenol. Whereas siRNA-mediated silencing clearly reduced the p65 content of the cells (A2, B2, C2), none of the bands detected by the four anti-P-p65 Ser276 antibodies was concomitantly reduced (A1, B1, B3, C1).
The p65 Ser276 residue is part of a consensus recognition site (RRXS) for PKA . To investigate whether perhaps the anti-P-p65 Ser276 antibodies crossreact with other PKA-regulated proteins, we investigated what happens to the anti-P-p65 Ser276-reactive bands upon silencing PKAcα. As evident from Figure 3 (A1, B1, B3), the isoproterenol-induced bands detected by all four anti-P-p65 Ser276 antibodies were almost completely inhibited in cells where PKAcα was (partially) silenced (A2, B2). Equal protein loading on the gels was confirmed by detection of the blots with anti-tubulin (Supplementary Figure 1) (the image in B3 was obtained upon stripping of the B blot after tubulin detection and reprobing with Cell Signaling no. 3037; knock-down and tubulin controls are, hence, the same as for B1).
3.4. Cell Signaling no. 3037 and SAB no. 11011 Do Not Detect Any Additional Immunoreactive Bands in p65 MEF Cells, Reconstituted with Wild Type p65, That Are Not Apparent in p65 MEF Cells
Whereas the siRNA-mediated knock-down of p65 was very efficient in the 1321N1 cells we used in this study, knock-down is never 100% complete. Therefore, we compared the immunoreactivity of the Cell Signaling no. 3037 and SAB no. 11011 antibodies in Western Blots from p65 knock-out MEF cells and MEF cells that had been reconstituted with either wild type p65 (p65 wt) or p65 with Ser276 mutated to alanine (p65 S/A). As apparent from Figure 4, the typical immunoreactive pattern (a prominent 130 kDa and a weak 80 kDa) band is also present in MEF cells that are deficient of p65. Unlike in the other investigated cell types, these bands seem to be present constitutively in MEF cells. In addition a 50 kDa band is induced by forskolin. Most importantly, not one single band is detected by either the Cell Signaling no. 3037 and SAB no. 11011 antibodies in p65 wt reconstituted MEF cells, that is not already present in p65 knock-out cells (Figure 4, A1 and B1), which clearly have no p65 (Figure 4, A2 and B2).
3.5. The Detected 80 kDa and 130 kDa Immunoreactivities Are Not p105/p50 or c-Rel
In the datasheet of the Cell Signaling no. 3037 antibody, it is mentioned that the antibody might crossreact with c-Rel and NF-κB1 (p105/p50) when phosphorylated at the homologous Ser267 and Ser337 residues, respectively. As c-Rel and NF-κB1 p105 have molecular weights of 70 and 105 kDa, respectively, upon phosphorylation they could theoretically appear as the 80 and 130 kDa bands we observed on Western Blot. We therefore investigated whether siRNA-mediated silencing of p105/p50 or c-Rel affected the appearance of these bands on Western Blot. As apparent from Figure 5, whereas we were able to efficiently inhibit the expression of c-Rel and p105, the intensity of the 80 and 130 kDa immunoreactive bands was unaltered, indicating they do not represent phosphorylated p105/p50 or c-Rel.
3.6. The Cell Signaling no. 3037 Antibody Recognizes p65 Ser276 Phosphorylation In Vitro
As the above described results indicate that the Cell Signaling no. 3037 antibody (as well as the other anti-P-p65 Ser276 antibodies we tested) does not allow detection of in vivo Ser276 phosphorylation of p65 via Western Blotting, we next assessed whether the Cell Signaling no. 3037 antibody recognized in vitro Ser276-phosphorylated p65. We therefore performed an in vitro kinase assay, using recombinant MSK-1 to phosphorylate a recombinant GST-p65 fusion protein. As demonstrated in Figure 6, we could indeed detect phosphorylation of GST-p65, that was blocked by preadsorption with the immunizing phosphopeptide (see dot blot), and that was inhibited by inclusion of the PKA/MSK-1 inhibitor H89 in the kinase reaction (see Western Blot). When a GST-p65 Ser276 to cysteine mutant (SC) was used in the kinase reaction, no immunoreactivity could be observed neither in the dot blot nor in the Western Blot, underlining the specificity of the recognition. These results indicate that, in vitro, the Cell Signaling anti-P-p65 Ser276 antibody recognizes Ser276-phosphorylated p65.
Here we show that, several commonly used antibodies, designed to detect Ser276-phosphorylated p65, react with other PKA-regulated proteins, but do not detect Ser276-phosphorylated p65 in vivo via Western Blotting.
According to the manufacturer’s data sheet, the Ser276-phosphorylated p65 band detected by the Cell Signaling no. 3037 antibody migrates at 80 kDa in denaturing gels. We indeed detected a weak 80 kDa band, that appears to be coregulated with a much more prominent 130 kDa band, in a variety of mouse and human cell types (L929sA, Raw264.7, C2C12, MEF cells, L363, A549, and 1321N1 cells) and upon treatment with different known inducers (LPS, PMA, TNF, forskolin, cAMP) of p65 Ser276 phosphorylation. In some cell types, visualization of the 80 kDa band required more sensitive fluorescent (Odyssey Imaging System, Licor, Lincoln, NA) development procedures than the standard HRP-based chemiluminescent detection we are routinely using. The 80 and 130 kDa bands disappeared upon preadsorption of the phosphospecific antibody with the phosphopeptide that was used for immunization, indicating they represent bands that are specifically recognized by the antibody.
We further investigated Ser276 phosphorylation of p65 mainly in the human 1321N1 astrocytoma cell line, upon treatment with the β-adrenergic agonist isoproterenol (to activate the PKA pathway) and with TNF-α (to activate MSK-1). In Western Blotting experiments, upon isoproterenol treatment, the 1321N1 cells exhibit the typical immunoreactive bands that are also detected by Cell Signaling no. 3037 in other cell types and upon different treatments: a very prominent 130 kDa band and a very weak 80 kDa band, which was also slightly induced by TNF-α. Our observation that all immunoreactive bands persisted upon siRNA-mediated silencing of p65 in 1321N1 cells, however, indicates that these bands are not posttranslationally modified forms of p65 (Figure 2). The successfulness of the siRNA approach to knock-out p65 was corroborated by the finding that silencing of p65 did inhibit TNF-α-induced p65 Ser536 phosphorylation (Figure 2). In line with these findings, using Cell Signaling anti-P-p65 Ser276, we were unable to detect the 130 kDa and 80 kDa immunoreactivities on Western Blot upon successful immunoprecipitation of endogenous p65 in lysates from isoproterenol-treated 1321N1 cells, whereas we did successfully recover Ser536-phoshorylated p65 (Supplementary Figure 2). In addition, we were also unable to detect any anti-P-p65 Ser276 immunoreactive bands when Flag-tagged p65 was transiently transfected and subsequently concentrated by anti-Flag immunoprecipitation (Supplementary Figure 3). We could however successfully detect Ser276-phosphorylated p65 with the Cell Signaling anti-P-p65 Ser276 using an in vitro kinase approach (Figure 6). These observations indicate that the Cell Signaling anti-P-p65 Ser276 antibody does specifically recognize the phosphorylated p65 Ser276 residue when p65 is present abundantly, and isolated from other possible crossreacting proteins, as is the case in the in vitro assay. However, in an in vivo situation, when p65 is present in a mixture of other proteins with a homologous phosphorylation sequence, the antibody clearly has a preference for other targets, that are either more abundant, are more efficiently phosphorylated, or have a higher affinity for the anti-P-p65 Ser276 antibodies than Ser276-phosphorylated p65. As we had identical results using different lot numbers of Cell Signaling no. 3037, as well as using anti-P-p65 Ser276 antibodies distributed by different companies (SAB no. 11011 and Rockland no. 100-401-264) and a homemade antibody (Figure 3), we believe our results are not artefactual. All investigated antibodies were probably generated with very similar synthetic phosphopeptides (i.e., MQLRRPpSDRELSE for the homemade antibody and QLRRPpSDRELSE for the Rockland no. 100-401-264 antibody). The sequence surrounding the p65 Ser276 residue resembles a PKA recognition site  and our observation, that siRNA-mediated silencing of PKAcα leads to disappearance of the anti-P-p65 Ser276-detected immunoreactivities (Figure 3), indicates the antibodies indeed detect PKA-phosphorylated proteins, but unfortunately not PKA-phosphorylated p65, in 1321N1 cells. The fact that we were unable to immunoprecipitate the inducible 80 or 130 kDa proteins using anti-P-p65 Ser276 (data not shown), hampers identification of the crossreacting proteins via mass spectrometric analysis.
Although our data indicate that in the 1321N1 cell line, the anti-P-p65 Ser276 antibodies we investigated do not detect Ser276-phosphorylated p65, but rather crossreact with other PKA-regulated proteins, we cannot claim, just by analogy, that the bands, recognized by these antibodies in other cell types, are neither Ser276-phosphorylated p65. We did, however, obtain uncircumstantial evidence that at least the Cell Signaling no. 3037 and SAB no. 11011 antibodies lack specificity for p65, by the observation that in lysates from p65-deficient MEF cells, and from p65 MEF cells reconstituted with wild type p65, the same immunoreactive bands are detected (Figure 4). In addition, in MEF cells, as in all other investigated cell types, constitutive immunoreactivities of 130 kDa and 80 kDa were apparent, indicating these bands probably represent crossreacting proteins that are abundantly present in most cell types.
Phosphorylation of p65 at the Ser276 residue has been extensively investigated in other cell types than the ones we have studied, yet several groups have demonstrated phosphorylation of p65 Ser276 via Western Blot in cells that we also investigated (Supplementary Table ), without reporting any peculiarities on the MW of the bands shown in the Western Blots. Only in a few of these publications, additional, antibody-independent, experiments were performed that support the involvement of p65 Ser276 phosphorylation and the conclusion of their studies.
The main conclusion from this study is that reports on the function of Ser276 phosphorylation of p65 should include additional, antibody-independent experiments. This, however, narrows down p65 phosphorylation research to the study of p65 cells, reconstituted with selected p65 point mutants. Very recently, the group that originally reported Ser276 phosphorylation by PKA , and, as a matter of fact, has never used the anti-P-p65-antibody approach, has generated a transgenic knock-in mouse with p65 Ser276 mutated to alanine . Still, for those interested in studying p65 phosphorylation in vivo in cells and tissues, phosphospecific antibodies are invaluable tools. We therefore believe it might be worthwhile to invest in the generation of a monoclonal anti-P-p65 Ser276 antibody, with a better specificity and selectivity profile than the currently available polyclonal antibodies.
In summary, we believe the take-home-message from our investigation is that caution is warranted in the interpretation of data generated using the abovedescribed anti-phospho-p65Ser276 antibodies.
The authors would like to thank all authors from whom they received feedback on their experience with the tested anti-P-p65Ser276 antibodies. They would also like to thank Professor P. Cohen for the kind gift of the homemade anti-P-p65Ser276 antibody. This work was supported by the FWO flanders. A. Spooren is a predoctoral FWO-fellow. L. Vermeulen and S. Gerlo are post-doctoral FWO-fellows. Financial support was also provided by Interuniversity Attraction Poles (IAP) P5/12 and by an institutional grant (GOA) from Ghent University.
- H. Singh, R. Sen, D. Baltimore, and P. A. Sharp, “A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes,” Nature, vol. 319, no. 6049, pp. 154–158, 1986.
- M. S. Hayden and S. Ghosh, “Shared principles in NF-B signaling,” Cell, vol. 132, no. 3, pp. 344–362, 2008.
- S. Ghosh and M. S. Hayden, “New regulators of NF-B in inflammation,” Nature Reviews Immunology, vol. 8, no. 11, pp. 837–848, 2008.
- P. Viatour, M.-P. Merville, V. Bours, and A. Chariot, “Phosphorylation of NF-B and IB proteins: implications in cancer and inflammation,” Trends in Biochemical Sciences, vol. 30, no. 1, pp. 43–52, 2005.
- L. Vermeulen, W. Vanden Berghe, and G. Haegeman, “Regulation of NF-B transcriptional activity,” Cancer Treatment and Research, vol. 130, pp. 89–102, 2006.
- M. L. Schmitz, I. Mattioli, H. Buss, and M. Kracht, “NF-B: a multifaceted transcription factor regulated at several levels,” ChemBioChem, vol. 5, no. 10, pp. 1348–1358, 2004.
- L.-F. Chen and W. C. Greene, “Shaping the nuclear action of NF-B,” Nature Reviews Molecular Cell Biology, vol. 5, no. 5, pp. 392–401, 2004.
- M. Neumann and M. Naumann, “Beyond IBs: alternative regulation of NF-B activity,” FASEB Journal, vol. 21, no. 11, pp. 2642–2654, 2007.
- H. Zhong, H. SuYang, H. Erdjument-Bromage, P. Tempst, and S. Ghosh, “The transcriptional activity of NF-B is regulated by the IB-associated PKAc subunit through a cyclic AMP-independent mechanism,” Cell, vol. 89, no. 3, pp. 413–424, 1997.
- L. Vermeulen, G. De Wilde, P. Van Damme, W. Vanden Berghe, and G. Haegeman, “Transcriptional activation of the NF-B p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1),” EMBO Journal, vol. 22, no. 6, pp. 1313–1324, 2003.
- H. Zhong, R. E. Voll, and S. Ghosh, “Phosphorylation of NF-B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300,” Molecular Cell, vol. 1, no. 5, pp. 661–671, 1998.
- J. Dong, E. Jimi, H. Zhong, M. S. Hayden, and S. Ghosh, “Repression of gene expression by unphosphorylated NF-B p65 through epigenetic mechanisms,” Genes and Development, vol. 22, no. 9, pp. 1159–1173, 2008.
- B. Vanhaesebroeck, S. Van Bladel, A. Lenaerts, et al., “Two discrete types of tumor necrosis factor-resistant cells derived from the same cell line,” Cancer Research, vol. 51, no. 9, pp. 2469–2477, 1991.
- C. Yoon, Z. Korade, and B. D. Carter, “Protein kinase A-induced phosphorylation of the p65 subunit of nuclear factor-B promotes Schwann cell differentiation into a myelinating phenotype,” The Journal of Neuroscience, vol. 28, no. 14, pp. 3738–3746, 2008.
- G. Mosialos and T. D. Gilmore, “v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence,” Oncogene, vol. 8, no. 3, pp. 721–730, 1993.